MRK - Merck & Co., Inc.

NYSE - NYSE Delayed Price. Currency in USD
89.65
-0.32 (-0.36%)
At close: 4:04PM EST

89.65 0.00 (0.00%)
After hours: 6:47PM EST

Stock chart is not supported by your current browser
Previous Close89.97
Open90.17
Bid89.51 x 1300
Ask90.10 x 1000
Day's Range89.62 - 90.46
52 Week Range72.05 - 92.64
Volume6,584,117
Avg. Volume8,415,338
Market Cap228.247B
Beta (5Y Monthly)0.53
PE Ratio (TTM)25.05
EPS (TTM)3.58
Earnings DateFeb 04, 2020
Forward Dividend & Yield2.44 (2.71%)
Ex-Dividend DateDec 11, 2019
1y Target Est99.06
  • Health stocks reverse coronavirus gains as one analyst says the market is overreacting
    Yahoo Finance

    Health stocks reverse coronavirus gains as one analyst says the market is overreacting

    Virus originating in Wuhan, China affected stock markets Tuesday, but one analyst said reactions were too strong.

  • J&J's (JNJ) Q4 Earnings Surpass Estimates, Sales Fall Short
    Zacks

    J&J's (JNJ) Q4 Earnings Surpass Estimates, Sales Fall Short

    J&J (JNJ) comes up with mixed fourth-quarter 2019 results.

  • Horizon Therapeutics Gets FDA Approval for Eye Drug Tepezza
    Zacks

    Horizon Therapeutics Gets FDA Approval for Eye Drug Tepezza

    Horizon Therapeutics' (HZNP) Tepezza becomes the first FDA-approved therapy for treating thyroid eye disease, a rare, autoimmune disease. Stock up.

  • 5 Big Drug/Biotech Stocks Set to Trump Q4 Earnings Estimates
    Zacks

    5 Big Drug/Biotech Stocks Set to Trump Q4 Earnings Estimates

    Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.

  • GlobeNewswire

    BriaCell Invited to Present at Mount Sinai’s Frontiers in Academic Pathology Symposium at The New York Academy of Medicine

    BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXD), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announced today that it will present at the “Frontiers in Academic Pathology” symposium, hosted by the Icahn School of Medicine at Mount Sinai, to be held on Friday, January 31, 2020 at The New York Academy of Medicine, 1216 Fifth Avenue in New York. The symposium focus will include molecular biomarkers, experimental diagnostics and liquid biopsies, all of which factor heavily in the development of BriaCell’s companion diagnostics under development, including BriaCell’s HLA-matching hypothesis and recently-announced Grade I/II biomarkers.

  • MarketWatch

    Dow drops 166 points on losses in Boeing, Chevron shares

    DOW UPDATE The Dow Jones Industrial Average is trading down Tuesday afternoon with shares of Boeing and Chevron seeing the biggest drops for the blue-chip average. Shares of Boeing (BA) and Chevron (CVX) are contributing to the index's intraday decline, as the Dow (DJIA) was most recently trading 166 points (0.

  • Value stocks are making a comeback, and here’s how to get in early
    MarketWatch

    Value stocks are making a comeback, and here’s how to get in early

    The U.S. stock market seems risky now because valuations are rich, as sentiment marches higher. Usually at such extremes, value stocks enter a sustained phase of outperformance — and that’s likely about to happen. “Ignore value at your peril,” says John Linehan, chief investment officer of equity at mutual-fund giant T. Rowe Price Group.

  • Business Wire

    FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in HRR-Mutated Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review

    FDA Accepts Regulatory Submission of sNDA for LYNPARZA in HRR-Mutated Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review

  • Is Merck & Co. (MRK) a Profitable Pick for Value Investors?
    Zacks

    Is Merck & Co. (MRK) a Profitable Pick for Value Investors?

    Merck & Co. (MRK) stock may be a good choice for value-oriented investors right now from multiple angles.

  • Seattle Genetics Up More Than 40% in the Past Year: Here's Why
    Zacks

    Seattle Genetics Up More Than 40% in the Past Year: Here's Why

    Seattle Genetics' (SGEN) Adcetris registers strong sales in 2019. The company wins an accelerated approval for Padcev to treat urothelial cancer while other pipeline candidates also progress well.

  • Significant Study on Veterinary Wellbeing Reveals Importance of Continued Focus on Personal and Professional Health and Wellbeing Among Veterinarians
    PR Newswire

    Significant Study on Veterinary Wellbeing Reveals Importance of Continued Focus on Personal and Professional Health and Wellbeing Among Veterinarians

    Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced the results of a comprehensive study of wellbeing and mental health among U.S. veterinarians, which are critical issues facing the veterinary profession. Conducted in collaboration with the American Veterinary Medical Association (AVMA), the Merck Animal Health Veterinarian Wellbeing Study also examined job satisfaction, compensation, burnout, substance use disorder, cyberbullying and suicide among veterinarians while evaluating potential solutions.

  • Reuters

    Drugmakers slash prices to be eligible for China's bulk-buy program

    Global pharmaceutical majors and generic drugmakers chopped by 53% on average prices of some of their off-patent products in the latest bidding round under China's national bulk-buy program, government officials said late on Friday. Beijing has been pushing forward the program where drugmakers have to go through a bidding process and cut prices low enough to be considered over generic copies and be allowed to sell their products at public hospitals via large-volume government procurement. Some global firms such as AstraZeneca and Merck have already cautioned about intensifying price pressures on their mature brands in the world's second largest drug market, as China expands the usage of the program.

  • Will J&J (JNJ) Roll Out Pharma Q4 Earnings With a Beat?
    Zacks

    Will J&J (JNJ) Roll Out Pharma Q4 Earnings With a Beat?

    J&J's (JNJ) cancer drugs are expected to have contributed significantly to fourth-quarter 2019 earnings. Generic/biosimilar headwinds are expected to have hurt Pharma unit's sales.

  • Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates
    Zacks

    Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates

    Lilly (LLY) offers to buy Dermira for $1.1 billion. AstraZeneca (AZN) and AbbVie (ABBV) provide pipeline updates.

  • Why Amarin Stock Is Poised for a Healthy 2020
    InvestorPlace

    Why Amarin Stock Is Poised for a Healthy 2020

    Amarin (NASDAQ:AMRN) stock has been choppy for the past year, as the price has made multiple attempts to move above the $23-$24 range. However, this has been a stubborn line of resistance, considering the stock price is currently around $20.Source: Pavel Kapysh / Shutterstock.com Despite this, Amarin stock has still been a pretty good bet over the years. After all, the five-year average return is close to 80%.So, what now? Could there be an opportunity with Amarin stock? Well, I think so.InvestorPlace - Stock Market News, Stock Advice & Trading TipsTo see why, let's get a brief backgrounder on the company. Founded in 1993, Amarin is one of the leaders in leveraging lipid science and polyunsaturated fatty acids to create pharmaceuticals to improve heart health. The main drug is Vascepa, which has posted robust growth. In the latest quarter, revenues hit $112.4 million, up 103% on a year-over-year basis. This has been due to substantial increases in the number of subscribers and higher levels of prescriptions per prescriber. * 10 Cheap Stocks to Buy Under $10 However, the key for Amarin is that it recently gained FDA approval for wider applications for Vascepa. This decision, ironically enough, came on Friday the 13th last month -- but of course, this really should be a very lucky day. Vascepa's DevelopmentThe new indication and label expansion -- which is the result of a decade of research and development -- is for a therapy to reduce "the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥150 mg/dL) and established cardiovascular disease or diabetes mellitus and two or more additional risk factors for cardiovascular disease."Yes, this is kind of medical jargon. But when boiling things down, the new use for Vascepa is a game changer.According to Dr. Deepak Bhatt, an executive director of the Interventional Cardiovascular Programs at Brigham and Women's Hospital Heart and Vascular Center, the treatment "represents one of the most important developments in the prevention and treatment of cardiovascular disease since statins…"The market opportunity is enormous, as there -- on average -- one cardiovascular death occurring every 40 seconds in the U.S. Also, the financial costs of cardiovascular disease events are burdensome at about $500 billion a year -- the most costly in the U.S. The CompetitionThere are a myriad of companies trying to do what Amarin has done; that is, using lipid therapies for cardiovascular disease. But, the science has proven quite complex and challenging.Note that there have been some recent examples of Phase 3 trials that shown disappointing results, such as from AstraZeneca (NYSE:AZN) and Acasti Pharma (NASDAQ:ACST). In fact, since December, ACST has plunged from $2.87 to around $0.80 per share.In fact, Cantor Fitzgerald analyst Louise Chen recently wrote after these companies' failures that "AMRN has been the only company in its class with an outcomes study (REDUCE-IT) that has shown a statistically significant benefit in reducing [cardiovascular] disease. We think the news today underscores our view that AMRN is an interesting asset in a consolidating space." Bottom Line On Amarin StockLast week, Amarin issued revised guidance for 2019. Revenues are now expected to range from $410 million to $425 million, which is at or slightly above the upper end of the prior forecast. The company also noted that beyond 2020, Vascepa's total net revenue "will grow to reach multiple billions of dollars" because "the history of other therapies for chronic conditions suggests that growth builds over multiple years."Given this, the growth story should be robust for quite some time. This should also stir up mergers & acquisitions interest from the mega pharma companies like Pfizer (NYSE:PFE), Merck (NYSE:MRK) and even AZN.Let's face it, they need to fill their pipelines with blockbuster drugs -- and these companies certainly have the resources to pay a premium price for Amarin.Tom Taulli is the author of the book, Artificial Intelligence Basics: A Non-Technical Introduction. Follow him on Twitter at @ttaulli. As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Cheap Stocks to Buy Under $10 * 5 Retail Stocks Placer.ai Thinks Can Win Big in 2020 * 6 Cheap Stocks to Buy Under $7 The post Why Amarin Stock Is Poised for a Healthy 2020 appeared first on InvestorPlace.

  • GuruFocus.com

    US Indexes Close Higher Wednesday With China Trade Deal Signing

    Dow Jones up 0.31% Continue reading...

  • Clovis Rubraca sNDA for Prostate Cancer Gets Priority Review
    Zacks

    Clovis Rubraca sNDA for Prostate Cancer Gets Priority Review

    Clovis' (CLVS) sNDA seeking label expansion of Rubraca to include BRCA-mutant advance prostate cancer gets priority review from the FDA. Stock up.

  • Bristol-Myers' Opdivo-Yervoy sBLA for NSCLC Accepted by FDA
    Zacks

    Bristol-Myers' Opdivo-Yervoy sBLA for NSCLC Accepted by FDA

    The FDA accepts Bristol-Myers' (BMY) sBLA for the Opdivo-Yervoy combo for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations.

  • Business Wire

    Merck Completes Acquisition of ArQule

    Merck Completes Acquisition of ArQule

  • MarketWatch

    Dow up 75 points on gains for UnitedHealth, Visa stocks

    DOW UPDATE Powered by strong returns for shares of UnitedHealth and Visa, the Dow Jones Industrial Average is trading up Wednesday afternoon. The Dow (DJIA) is trading 77 points, or 0.3%, higher, as shares of UnitedHealth (UNH) and Visa (V) have contributed around 25% of the index's intraday rally.

  • Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?
    Zacks

    Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?

    Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • MarketWatch

    UnitedHealth, Pfizer share gains lead Dow's 150-point climb

    DOW UPDATE Shares of UnitedHealth and Pfizer are posting positive momentum Wednesday morning, sending the Dow Jones Industrial Average into positive territory. The Dow (DJIA) is trading 153 points, or 0.

  • BioLineRx's Pancreatic Cancer Drug Gets Orphan Drug Tag in EU
    Zacks

    BioLineRx's Pancreatic Cancer Drug Gets Orphan Drug Tag in EU

    The European Commission bestows an orphan drug status on BioLineRx's (BLRX) lead candidate Motixafortide, currently being evaluated with Merck's Keytruda to treat pancreatic cancer. Stock up.

  • MarketWatch

    Dow's 75-point climb led by gains in UnitedHealth, Pfizer stocks

    DOW UPDATE Shares of UnitedHealth and Pfizer are posting positive growth Wednesday morning, propelling the Dow Jones Industrial Average into positive territory. Shares of UnitedHealth (UNH) and Pfizer (PFE) are contributing to the index's intraday rally, as the Dow (DJIA) is trading 78 points, or 0.

  • Merck (MRK) Gains As Market Dips: What You Should Know
    Zacks

    Merck (MRK) Gains As Market Dips: What You Should Know

    In the latest trading session, Merck (MRK) closed at $89.92, marking a +0.46% move from the previous day.